All In Biotech

Drug Trial Radar · NCT07222917

A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

222

Actual

Start

Dec 5, 2025

Primary completion

Dec 10, 2026

Study completion Dec 10, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.

Conditions

  • Chronic Kidney Disease and Hypertension

Interventions

  • Baxdrostat/dapagliflozinDrug

    baxdrostat tablet dapagliflozin tablet

  • Baxdrostat/PlaceboDrug

    baxdrostat tablet placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine whether baxdrostat/dapagliflozin is superior to baxdrostat/matching placebo at reducing albuminuria.Time frame: Up to 12 weeks

Locations

55 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Surprise, Arizona

  • Research Site

    Hollywood, Florida

  • Research Site

    Port Charlotte, Florida

  • Research Site

    Port Orange, Florida

  • Research Site

    East Point, Georgia

  • Research Site

    Champaign, Illinois

  • Research Site

    Wichita, Kansas

  • Research Site

    Greenville, North Carolina

  • Research Site

    Jacksonville, North Carolina

  • Research Site

    New Bern, North Carolina

  • Research Site

    Columbus, Ohio

  • Research Site

    Media, Pennsylvania

  • Research Site

    East Providence, Rhode Island

  • Research Site

    Arlington, Texas

  • Research Site

    Pasadena, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Woodbridge, Virginia

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Mar del Plata, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    San Nicolás, Argentina

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Yambol, Bulgaria

  • Research Site

    Courtice, Ontario, Canada

  • Research Site

    Etobicoke, Ontario, Canada

  • Research Site

    Stouffville, Ontario, Canada

  • Research Site

    Waterloo, Ontario, Canada

  • Research Site

    Kaohsiung City, Taiwan

  • Research Site

    Kaohsiung City, Taiwan

  • Research Site

    New Taipei City, Taiwan

  • Research Site

    Taichung, Taiwan

  • Research Site

    Taichung, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taoyuan, Taiwan

  • Research Site

    Bangkoknoi, Thailand

  • Research Site

    Changwat Sara Buri, Thailand

  • Research Site

    Hat Yai, Thailand

  • Research Site

    Ratchathewi, Thailand

  • Research Site

    Adana, Turkey (Türkiye)

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.